Retrospective analysis of adjuvant therapy using dabrafenib plus trametinib in Japanese patients with advanced melanoma: Analysis of 36 cases

Ryo Amagai, Yusuke Muto, Hiroshi Kato, Shigeto Matsushita, Takeo Maekawa, Satoshi Fukushima, Koji Yoshino, Hiroshi Uchi, Yasuhiro Fujisawa, Yuki Yamamoto, Kentaro Ohuchi, Yumi Kambayashi, Taku Fujimura

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

Patients with resected stage IIIB, IIIC and IIID melanomas have a high risk of recurrence. Therefore, an appropriate protocol for stage III melanoma is needed. Since adjuvant dabrafenib plus trametinib (D+T) combined therapy and anti-PD1 antibody (Ab) therapy reduce the risk of recurrence in patients with resected stage III BRAF-mutated melanoma, selecting the adjuvant therapy for BRAF-mutated melanoma is controversial. The efficacy and safety profiles of D+T combined therapy in the adjuvant setting were retrospectively analyzed in 36 Japanese. BRAF-mutated advanced melanoma patients. The relapse-free rate (RFR) at 12 months was 82.1% (95% confidential interval (CI), 63.9-92.6%). In the 21 patients who completed the protocol, the RFR at 12 months was 85.7% (95% CI, 64.5-95.9%). In the seven patients whose protocol was interrupted by adverse events, the RFR was 71.4% (95% CI, 35.2-92.4%). The incidence rate of any AEs for all patients was 69.7% (95% CI, 52.5-82.8%), including 13 cases of pyrexia, five cases of skin rash and four cases of liver dysfunction. The present study suggested that D+T therapy in the adjuvant setting is a useful and very tolerable protocol for BRAF-mutated melanoma in the Japanese population.

Original languageEnglish
Pages (from-to)575-578
Number of pages4
JournalMelanoma Research
Volume31
Issue number6
DOIs
Publication statusPublished - 2021 Dec 1

Keywords

  • BRAF-mutated melanoma
  • adjuvant therapy
  • adverse events
  • relapse-free rate (RFR)

Fingerprint

Dive into the research topics of 'Retrospective analysis of adjuvant therapy using dabrafenib plus trametinib in Japanese patients with advanced melanoma: Analysis of 36 cases'. Together they form a unique fingerprint.

Cite this